Overview

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Bryan Allen

Collaborator:

Holden Comprehensive Cancer Center

Treatments:

Ascorbic Acid
Ferrosoferric Oxide
Temozolomide